UBS upgrades Jabil, citing AI, healthcare, and automation growth with a $430 price target.

UBS upgraded Jabil Inc to 'Buy' and raised its earnings estimates, driven by strong growth prospects in AI, healthcare, and automation sectors. The firm expects Jabil's AI-related revenue to grow about 50% in fiscal 2027, supported by capacity expansions and key customers like Amazon and Meta. Healthcare growth is expected from new capacity in Croatia, focusing on higher-margin products. UBS raised earnings-per-share forecasts for 2027 and 2028, anticipating operating margin improvements and a multiyear growth cycle despite a lower valuation multiple, maintaining a $430 price target with roughly 22% upside potential.